Meningococcal serogroup B vaccines: will they live up to expectations?

Click to increase image sizeClick to decrease image size

Disclaimer

The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the US Department of Defense.

Acknowledgements

The photograph of Martin CJ Maiden was obtained by courtesy of Mark FJ Maiden, the copyright owner.

Financial & competing interests disclosure

Jan T Poolman is an employee of GlaxoSmithKline Biologicals S.A. (GSK). He owns shares and options to shares in GSK. In addition, Jan T Poolman is a designated inventor on a variety of patents owned by GSK. Wendell D Zollinger and Martin CJ Maiden are named as inventors or contributors on patent applications in the area of serogroup B meningococcal vaccine development. They also occasionally consult for various commercial companies in this area. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing assistance by Joanne Wolter was financed by GSK. No other writing assistance was utilized in the production of this manuscript.